Propanc Biopharma Submits Orphan Drug Designation Request to the US Food and Drug Administration for Treatment of Ovarian Cancer Oct 25, 2017
Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies Aug 30, 2017
Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study Aug 2, 2017
Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China Jul 20, 2017
